Beyond Document Delivery: How a Compliance-First CER Strategy Helped Achieve a Successful Notified Body Review

Introduction

For many medical device manufacturers, the success of a Clinical Evaluation Report (CER) is often measured by whether it is delivered on time. Under the European Medical Device Regulation (EU MDR 2017/745), however, success is measured very differently. A CER must demonstrate that a device is safe, performs as intended, and maintains a favorable benefit-risk profile based on robust clinical evidence. More importantly, it must withstand detailed scientific scrutiny from Notified Bodies.

As regulatory expectations continue to evolve, manufacturers are finding that preparing a compliant document is only part of the challenge. The real objective is achieving a smooth regulatory review with documentation that is consistent, traceable, and aligned across the entire Technical Documentation. This shift is changing how organizations approach clinical evaluation from simply producing documents to delivering regulatory outcomes.

Why Notified Bodies Raise Findings on CERs

Notified Bodies do not evaluate a CER in isolation. They assess whether the clinical evidence supports the intended purpose, claims, and risk profile of the device while remaining consistent with the broader Technical Documentation.

Some of the most common reasons Notified Bodies raise observations include:

• Incomplete or poorly justified systematic literature reviews.
• Weak linkage between clinical evidence, risk management, and benefit-risk conclusions.
• Insufficient justification for equivalence claims.
• Outdated or incomplete State-of-the-Art evaluations.
• Lack of consistency between the CER, Clinical Evaluation Plan (CEP), PMS, PMCF, and Technical Documentation.
• Limited traceability between clinical evidence and regulatory conclusions.
• Inadequate integration of post-market clinical data.

Many of these findings are avoidable when regulatory strategy and scientific evaluation are considered early rather than addressed during review.

A Compliance-First Success Story

Recently, our regulatory team partnered with a global consumer healthcare manufacturer to support the development of a Clinical Evaluation Plan (CEP) and Clinical Evaluation Report (CER) for one of its medical devices.

Rather than treating the engagement as a documentation exercise, the team adopted a compliance-first approach. During the evaluation, regulatory experts identified several known clinical risks that required stronger scientific justification. These observations were proactively addressed within the CER, ensuring that the clinical rationale, evidence, and benefit-risk assessment were aligned before submission.

The outcome demonstrated the value of this approach. During the Notified Body technical review, there were no findings directly related to the CEP or CER. The only follow-up concerned the document signature workflow rather than the scientific content itself.

For the manufacturer, this meant fewer review comments, reduced rework, and greater confidence heading into future regulatory and quality audits.

Why Compliance-First Thinking Reduces Review Cycles

Many organizations still focus on completing documentation as quickly as possible. While speed is important, quality and regulatory defensibility have a much greater impact on overall project timelines.

A compliance-first approach helps reduce review cycles by:

• Identifying evidence gaps before submission.
• Strengthening benefit-risk justifications early in the process.
• Maintaining consistency across Technical Documentation.
• Ensuring complete traceability between evidence and conclusions.
• Reducing the likelihood of avoidable Notified Body observations.

The result is not simply a completed CER – it is documentation that is better prepared for regulatory scrutiny.

Lessons for Manufacturers

Several practical lessons emerge from this experience. Start clinical evaluation with strategy rather than document creation. Address evidence gaps before submission rather than during Notified Body review. Maintain clear links between CERs, risk management, PMS, PMCF, and technical documentation. Finally, establish structured processes that preserve knowledge and simplify future maintenance activities.

Looking Ahead

Clinical evaluation is no longer a one-time milestone. Manufacturers must continuously maintain evidence, update documentation, and demonstrate ongoing compliance. Organizations that invest in repeatable, traceable processes are better positioned to reduce regulatory risk, improve efficiency, and respond confidently to changing expectations.

From Documents to Regulatory Outcomes

Maintaining EU MDR compliance has become increasingly complex, particularly for manufacturers managing multiple devices and recurring documentation updates. Success depends not only on creating compliant reports but also on establishing repeatable processes that improve consistency, preserve knowledge, and simplify future maintenance.

This reflects a broader shift across the medical device industry. Manufacturers are increasingly looking beyond vendors that simply produce documents. They want regulatory partners who understand the complete lifecycle—from clinical strategy and evidence generation to Notified Body review and post-market maintenance.

At Celegence, this philosophy is reflected in a simple belief:

Documents are the deliverable. Outcomes are what we deliver.

By combining regulatory expertise, accelerated by AI, manufacturers can build audit-ready clinical documentation that supports stronger regulatory outcomes while making every maintenance cycle more efficient than the last.

Looking to strengthen your CER strategy?

Whether you’re preparing for an initial EU MDR submission or maintaining an existing device portfolio, Celegence helps manufacturers build scientifically robust, audit-ready clinical documentation designed to support successful regulatory outcomes. Contact our regulatory experts to discuss your Clinical Evaluation strategy.